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SUMMARY

Tumor-associated macrophages (TAMs) play an important role in tumor immunity and comprise of subsets
that have distinct phenotype, function, and ontology. Transcriptomic analyses of human medulloblastoma,
the most common malignant pediatric brain cancer, showed that medulloblastomas (MBs) with activated
sonic hedgehog signaling (SHH-MB) have significantly more TAMs than other MB subtypes. Therefore, we
examined MB-associated TAMs by single-cell RNA sequencing of autochthonous murine SHH-MB at steady
state and under two distinct treatment modalities: molecular-targeted inhibitor and radiation. Our analyses
reveal significant TAM heterogeneity, identify markers of ontologically distinct TAM subsets, and show the
impact of brain microenvironment on the differentiation of tumor-infiltrating monocytes. TAM composition
undergoes dramatic changes with treatment and differs significantly between molecular-targeted and radiation therapy. We identify an immunosuppressive monocyte-derived TAM subset that emerges with radiation
therapy and demonstrate its role in regulating T cell and neutrophil infiltration in MB.

INTRODUCTION
Medulloblastoma (MB) is the most common malignant brain tumor of childhood, accounting for more than 20% of pediatric
brain tumors. It is biologically heterogeneous, comprising four
major molecular subgroups: WNT, sonic hedgehog (SHH), group
3, and group 4. Given the high-grade nature of this tumor type,
treatment is aggressive and involves surgical resection, chemotherapy, and radiation. MB are radiosensitive, but radiation can
lead to severe neurological side effects, which limits its use in
young children. Prognosis depends on multiple characteristics
of the tumor and is worse for patients in the high-risk stratifica-

tion. Overall survival for these patients has been estimated to
be from 50% to 75% (Bouffet, 2021). Recent identification of
activating pathways in MB provide opportunities for moleculartargeted therapy. Inhibitors of the SHH pathway, such as
GDC-0449 (vismodegib), have shown remarkable efficacy in
treating murine SHH-MB and human patients in clinical trials
(Robinson et al., 2015; Romer et al., 2004). However, development of resistance to GDC-0449 remains a concern, and the
drug is contraindicated in children under the age of 10 because
of its negative impact on bone growth (Dijkgraaf et al., 2011; Gajjar et al., 2013; Robinson et al., 2017). Hence, there is an urgent
need for novel therapeutics in high-grade MB.
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Incorporation of immunotherapy into standard clinical care for
several cancer types has stimulated significant interest in the tumor immune microenvironment. Brain tumors often harbor
numerous TAMs, but their composition and function remain unclear (Guadagno et al., 2018). Studies in non-CNS solid tumors
have shown that anti-inflammatory (M2 polarized) macrophages
drive immunosuppression, whereas pro-inflammatory (M1 polarized) macrophages support anti-tumor immunity. TAMs are also
emerging as predictors of clinical outcome, and modulation of
their function and recruitment by various drugs are in clinical tri€ller et al., 2017). Nonetheless, whether
als (Lee et al., 2018; Mu
macrophages can be targeted for immunotherapy of brain tumors remains unclear. A major barrier is our incomplete understanding of TAMs in the brain. In normal tissue, macrophages
display remarkable heterogeneity with regards to function,
€ddemann, 2017). Whether
phenotype, and origin (Gordon and Plu
TAMs in MB display similar heterogeneity is unknown. Furthermore, most published TAM descriptions relate to steady state,
and there is a major gap in our understanding of how the TAM
compartment changes under therapy. Addressing these knowledge gaps is key to conceptualizing new immunotherapeutic approaches in brain tumor.
The immune microenvironment varies significantly across tumor types (Binnewies et al., 2018). Most studies of macrophages
in brain tumors have been done in gliomas, and we know little
about these cells in MB. In addition, most TAM studies are based
on immunohistochemistry, flow cytometry, or transcriptional
profiling of bulk tumor tissue, methods that have limited capacity
to resolve cellular heterogeneity. As an example, a previous
study showed increased overall macrophage infiltration in
SHH-MB compared with other MB subtypes without further
elucidating TAM subsets (Margol et al., 2015). Single-cell RNA
sequencing (scRNA-seq) overcomes this limitation and is beginning to provide unprecedented insight into cellular heterogeneity
in solid tumors (Chung et al., 2017; Gubin et al., 2018). This is
exemplified by scRNA-seq of human MB, which provided new
insight into tumor cell heterogeneity, but few macrophages
were captured, precluding detailed analyses of TAMs (Hovestadt
et al., 2019). Current technical and computational limitations
restrict the number of cells that can be simultaneously analyzed
by scRNA-seq. Hence, approaches that analyze all cells in the
tumor are capable of providing an overview of cellular composition but have limited power to resolve heterogeneity within specific cell types. This is particularly true for cells that are relatively
rare compared with tumor cells within the tumor microenvironment. Enrichment and targeted scRNA-seq of the cell type of
interest in the tumor microenvironment will help overcome this
limitation but has not been explored in MB.
In this study, we first analyzed bulk RNA sequencing (RNA-seq)
from human MB collected by the newly established Open Pediatric Brain Tumor Atlas (OpenPBTA) and ascertained significant
infiltration by both monocyte- and microglia-derived TAMs. We
found SHH-MB to be enriched for TAMs compared with other
subtypes. Hence, we used a genetically engineered
Ptch1+/Tp53/ murine model of SHH-MB to further characterize TAMs in MB. We performed scRNA-seq of myeloid cells
from tumor-harboring cerebella of these mice. scRNA-seq is an
unbiased approach that can also capture novel and/or rare TAM
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subsets by sequencing all myeloid cells while analyzing all cerebellar myeloid cells. This overcomes technical hurdles associated
with isolating macrophages specifically residing within the tumor
microenvironment. We validated key findings from this unbiased
approach with various histology-based methods to confirm relevance to the MB microenvironment. Our analyses identified
monocyte- and microglia-derived TAMs, revealed significant heterogeneity in transcriptomic profile within both ontological subsets of TAMs, and established specific markers of these subsets.
We also uncovered unanticipated differences in TAM composition in response to radiation and molecular-targeted therapy
with GDC-0449 in our preclinical model. Further analyses led to
the identification of monocyte-derived macrophages with immunosuppressive characteristics that accumulate in the tumor after
radiation therapy. Importantly, genetic ablation of circulating
monocytes (Mono) prevented emergence of immunosuppressive
TAMs and was associated with significantly increased CD8 T cells
and neutrophils. Altogether, our study establishes a dataset of a
single-cell transcriptional profile of TAMs in SHH-MB at steady
state and under distinct treatment modalities, demonstrates the
value of this dataset by providing new insight into these TAMs,
and uncovers a potential path to combinatorial immunotherapy
in MB by revealing an immunoregulatory subpopulation of TAM
with radiation therapy.
RESULTS
Human MB displays transcriptional signature of both
microglia and monocyte-derived macrophages
Previous immunohistochemistry-based studies suggested
enhanced macrophage infiltration in human SHH-MB (Margol
et al., 2015). To elucidate TAM composition in MB, we analyzed
deconvoluted bulk RNA-seq data from 123 patients comprising
all four molecular subtypes of MB. This dataset was generated
from biopsy samples of patients as a part of the collaborative
OpenPBTA project. To estimate immune infiltration, we used
microenvironment cell populations counter (MCP-counter) (Becht
et al., 2016), an analysis method that quantifies abundance of
eight immune and two stromal cell populations in heterogeneous
tissues from RNA data. We found the SHH subtype to be significantly enriched for Mono, macrophages, T cells, and B cells (Figure 1A). In contrast, WNT tumors were enriched for natural killer
cells and group 4 tumors were enriched for neutrophils (Figure 1A).
We performed similar analyses of the data using two additional
methods: xCell and CIBERSORT (Figure S1A). CIBERSORT analysis was consistent with MCP-counter in identifying SHH-MB as
the subtype with the highest signature of all macrophage subtypes. As expected with different computational methods, minor
discrepancies were noted. For example, xCell estimated that
WNT tumors have a higher signature of M2 macrophages,
whereas SHH-MBs are highest for M1 macrophage markers.
Next, we performed analyses using BRETIGEA (McKenzie
et al., 2018), an R package that uses cell-type-specific genes
for cell-type proportion estimation from bulk RNA-seq, finding
that all MBs contain both microglia- and monocyte-derived
TAMs at varying proportions (Figure 1B). Based on this analyses,
group 4 appeared to harbor more Mono compared with microglia (Mg) (Wilcoxon p = 1.6e5), whereas SHH and WNT
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Figure 1. Human MBs display immune infiltration and variations in myeloid composition
(A) MCP-counter-based analysis of cellular composition using bulk RNA-seq of 123 human pediatric MBs. SHH-MBs show higher infiltration with lymphocytes
and myeloid cells compared with other MB subtypes.
(B) BRETIGEA cell proportion analysis of aforementioned human MB RNA-seq data shows the co-existence of microglia (Mg) and monocytes (Mono) in human
MB in varying proportions. OPC, oligodendrocyte precursor cell; Oli, oligodendrocytes; End, endothelial cells; Ast, astrocytes; Neu, neurons.
(C) Surrogate proportion variables (SPVs) of Mono are higher than of those Mg in group 4 MBs, whereas in SHH and WNT groups, Mic SPVs are higher than those
of Mono.
See also Figure S1.

subtypes (Wilcoxon p = 0.026 and 0.022, respectively) have
more Mg than Mono (Figure 1C). Hence, the extent and composition of TAMs in MB depends on the molecular subtype, with
SHH-MB harboring the most TAMs.
Single-cell analyses of myeloid infiltrates in murine
SHH-MB
Based on the observed enrichment of TAMs in human SHH-MB,
we decided to study these cells in an established

Ptch1+/Tp53/ murine model of SHH-MB (Goodrich et al.,
1997; Wetmore et al., 2001).These mice develop tumors on
average by 6 weeks of age. By 8 weeks, 100% of mice display
tumors (Figure 2A), and all mice die by 12 weeks of age. Murine
SHH-MB contained significantly more macrophages than surrounding normal cerebella tissue based on two established brain
macrophage markers, IbaI (p = 0.0023) and F4/80 (p % 0.0001)
(Figure 2B). To study macrophage heterogeneity, we performed
scRNA-seq (103 genomics) on CD11b+ myeloid cells isolated
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Figure 2. Murine SHH-MBs display abundant macrophages in the tumor microenvironment
(A) MRI of a representative Ptch1+/Tp53/ tumor at 8 weeks of age.
(B) Immunohistochemistry with Iba1 and F4/80 showing significantly higher macrophages in tumors compared with surrounding normal cerebellum.
Student’s t test. n = 3 animals. Results are expressed as mean ± SEM. **p < 0.01, ****p < 0.0001. Field: 4,345 3 3,260 mm. Scale bar: 500 and 200 mM.

from the following samples from male Ptch1+/Tp53/ mice: (1)
pooled cerebella from 3 mice that were 2 weeks old with no to
minimal tumors (as control for homeostatic Mg in normal tissue),
(2) pooled peripheral blood of the same 3 mice (as the source for
control circulating Mono), and (3) two samples of cerebellum of
8-week-old mice harboring large tumors (as the source of tumor-associated myeloid cells). We chose to analyze young
Ptch1+/Tp53/ mice, before they developed MB, for the control Mg and Mono instead of age-matched wild-type (WT) mice
to maintain a consistent genotype across all samples. Data
were analyzed using Seurat v.3.2.2 (Butler et al., 2018; Stuart
et al., 2019). We identified the major immune cell types using SingleR (Aran et al., 2019), an annotation method that uses a userprovided reference dataset of cell-type-specific gene expression to label cells. We used the Immgen microarray database,
which contains 830 samples representing 20 main hematopoietic and immune cell types, as our reference dataset for SingleR
(Heng et al., 2008).
Analyses of peripheral blood CD11b+ cells with SingleR identified the expected myeloid cells, including Mono (Figure S1B).
Analyses of myeloid cells of normal cerebella of 2-week-old
mice confirmed Mg as the dominant population (Figure S1C).
Next, we aggregated these datasets with the two samples of
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myeloid cells isolated from tumor-bearing cerebella of 8-weekold mice. The unfiltered aggregate of all four datasets is shown
in Figure S1D, and myeloid cells from two tumor samples are
shown separately in Figure S1E. Data are displayed in uniform
manifold approximation and projection (UMAP) dimension
reduction (Figures S1D and S1E). Clustering of aggregated
data using a resolution of 0.6 in Seurat identified 17 clusters.
Cluster 3 contained Mono, and those expressing high levels of
Ly6c2 and Ccr2 were identified as classical Mono (Figure S1F).
Among Mono, the classical subset (compared with patrolling
Mono) preferentially infiltrates tumors and inflamed tissue (Olingy
et al., 2019). Consistent with this, classical Mono were close to
TAMs in UMAP displays, suggesting an ontological relationship
(Figures 3A and 3B). Given our focus on TAM and its Mono precursor, we removed all circulating myeloid cells, except classical
Mono, from our aggregated dataset for further analyses. Mono
assigned to cluster 3 were present in both tumor samples (Figure S1E). For downstream analysis, we preserved peripheral
Mono in cluster 3 and removed Mono that came from tumors.
Similarly, cells annotated as Mg from tumor samples in cluster
0 were removed to retain only Mg from cerebellum of young
mice. This filtering was performed to disentangle the impact of
the tumor on gene expression in Mono and Mg. All other myeloid
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Figure 3. Single-cell RNA sequencing demonstrates myeloid heterogeneity in murine SHH-MB
(A) UMAP plot colored by sample. Pink cells are Mic from 2-week Ptch1+/Tp53/ cerebella. Green cells are classical Mono from peripheral blood of same-age
mice. Blue cells are from adult, tumor-bearing Ptch1+/Tp53/ mice.
(B) Seurat-based clustering of each subpopulation.
(C) SingleR annotation of subpopulations showing clusters 2 and 4 are microglia, clusters 8 and 1 are monocytes or macrophages, and cluster 6 comprises some
cells most similar to macrophages and some cells more similar to microglia.
(D and E) Heatmap of the expression of the top 30 (D) and 4 select (E) genes of each reference label by myeloid cells in the test dataset, which are assigned that
label to demonstrate confidence in the label assignment.
(F) Unbiased Monocle-based pseudotime analysis of the scRNA-seq data showing cells of clusters 2 and 4 are more similar to microglia (MG) and cells of clusters
1, 8, and 6 are more similar to monocytes (Mono).
See also Figures S1–S4.

cells from the tumors were retained. The filtered aggregate
labeled by sample type is shown in Figure 3A, and Seurat-based
clustering is shown in Figure 3B.
We performed cell annotation of this filtered aggregate using
SingleR (Figure 3C). As expected, this identified cluster 0 as
Mg and cluster 3 as Mono. In addition, clusters 2 and 4, which
are close to cluster 0, were identified as being most similar to
Mg. Clusters 1, 8, and 6 were proximal to Mono. Cluster 8 contains a mixture of cells assigned as Mono and macrophages,
whereas most of cluster 1 is similar to macrophages. The term
macrophages is used here for cells identified by SingleR to
display a gene expression signature generic to all macrophages.
In contrast, Mg is a specialized brain-resident macrophage and
is identified based on genes that are selectively expressed in Mg.

Interestingly, cluster 6 contained a mix of cells that were similar
to either Mg or macrophages. After macrophages, Mg, and
Mono, the largest myeloid cluster was identified as neutrophils
(Figure 3C). As validation of the cellular identity assigned by SingleR, we confirmed the expression pattern of the top 30 genes
specific to the four major myeloid clusters (Figure 3D). We also
showed expression of four genes that are considered hallmarks
of these cell types (Figure 3E).
To examine relationships among cell clusters, we analyzed the
filtered dataset using Monocle (v.2) pseudotime analysis (Trapnell et al., 2014), which plots all cells along a linear trajectory
based on transcriptomic similarity. We performed this analysis
in an unbiased manner without prior assignment of specific
genes. Consistent with the aforementioned findings, clusters 2
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Figure 4. Tumor-associated macrophages are heterogeneous
(A) Seurat-based cluster (left) and heatmap of top candidate genes distinguishing tumor-associated microglia (TAMg) from monocyte-derived macrophages.
(B) Cells of cluster 6 have the highest expression of microglia-specific genes.
(C) RNAvelocity analysis of a tumor-associated, monocyte-derived macrophage showing sequential differentiation of monocytes of cluster 3 to macrophages of
cluster 8, cluster 1, and finally cluster 6.
(D) Dotplot demonstrating expression of microglia- and monocyte-specific markers by the various clusters.
(E) qRT-PCR of selected genes specific to microglia and monocyte in CD11b+CD45hiLy6GLy6chi (predicted to correspond to cluster 8) and CD11b+CD45hiLy6GLy6clo cells (predicted to correspond to clusters 1 and 6) is consistent with scRNA-seq data. Student’s t test. n = 3 animals. Results are expressed as mean
± SEM. *p % 0.05, **p % 0.01.

(legend continued on next page)
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and 4 were most similar to Mg of cluster 0, whereas clusters 1, 8,
and 6 were most similar to Mono of cluster 3 (Figure 3F). Hence,
SHH-MB significantly alters the composition of cerebellar macrophages and induces the appearance of TAMs with a gene
expression signature suggestive of Mono and Mg origins.
Distinct ontological subsets of TAM display
characteristic genetic markers and differentiation
trajectory
Based on the aforementioned Seurat clustering and UMAP
dimensional reduction, cell annotation by SingleR, and Monocle
analysis, we define clusters 1, 8, and 6 as TAMs most similar to
Mono or monocyte-derived TAMs (TAMoMacs) and clusters 2
and 4 as TAMs most similar to Mg (TAMgs) (Figure 4A). Adult tissue macrophages originate from two major sources: embryonic
€ ddemann, 2017).
precursors or circulating Mono (Gordon and Plu
Mg is a prototypical embryonic-derived macrophage, but injury
and inflammation can recruit monocyte-derived macrophages
in brain (Ginhoux et al., 2013). Histologically, resting Mg has a
characteristic ramified appearance but upon activation changes
its morphology to an amoeboidal form, becoming indistinguishable from monocyte-derived macrophages. Previous studies
have proposed markers to distinguish these ontological subsets.
Studies in normal brain and in diseases such as Alzheimer and
neuroinflammation have put forth marker genes such as
Tmem119, P2ry12, Siglech, Fcrls, Olfml3, and Sparc for Mg
and Ms4a7 and Clec12a for monocyte-derived macrophages
(Bennett et al., 2016, 2018; Butovsky et al., 2014; Konishi
et al., 2017). Within brain tumors specifically, studies in glioma
proposed P2ry12, Tmem119, Slc2a5, and Fcrls for tumor-infiltrating Mg and Itga4, Emilin2, Gda, Hp, and Sell for tumor-infiltrating, monocyte-derived macrophages (Bowman et al., 2016;
Haage et al., 2019). Whether these markers change with tumor
types or disease contexts is unclear. Hence, we examined their
expression in our scRNA-seq dataset. Unexpectedly, we found
that most of these proposed markers did not distinguish the
two ontological subsets in SHH-MB because either TAMoMacs
did not highly express the Mono-associated markers or a large
portion of TAMoMacs also expressed the Mg-associated
markers (Figure S2A). Thus, we aimed to identify better markers
of TAM origins in SHH-MB using our dataset.
Our first step was to create a list of genes differentially expressed between Mg or circulating classical Mono cells using
the FindMarkers function in Seurat with all default settings,
including a logfc threshold of 0.25, use of Wilcoxon rank-sum
test, and the min.pct set at 0.1. From this list, we identified
Mg- or Mono-associated candidate genes by first selecting
only those that showed at least 2-fold change between the cell
types. We then asked what percentage of normal Mg or Mono
expressed each of these genes. Mg-associated gene candidates were identified as those that were expressed in R50%
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more cells in the Mg population compared with the Mono population, and the converse were identified for the Mono-associated
candidates. 84 genes met these criteria for Mono-associated
genes, and 115 genes met these criteria for Mg-associated
genes.
In the second step, we compared the expression levels of the
84 Mono-associated genes between TAMgs and TAMoMacs.
Mono-specific genes that were expressed in greater than 50%
of TAMoMacs but less than 10% of TAMgs were designated
as markers for monocyte-derived macrophages (Mono specific).
Nine genes met these criteria (Ccr2, Clec4a3, Clec12a, Ly6c2,
Plbd1, S100a11, S100a6, Tgfbi, and Vim) (Figure 4A). However,
this approach/criteria to narrow Mg-specific markers among
the Mg-associated genes was not successful, because most of
them were also expressed by at least 30% of TAMoMacs (Figure S2B). This may suggest that when Mono enter the brain
and differentiate into macrophages, the brain environment induces expression of genes normally seen in resident Mg. This
notion of microenvironmental impact on brain macrophage
gene expression is consistent with prior reports (Bennett et al.,
2018; Bowman et al., 2016). We next elected to analyze the
top 10 genes (Olfml3, Siglech, Tmem119, Hpgds, Gpr34,
P2ry12, Fcrls, Serpine2, Ttr, and Sparc) (Figure 4A) that were
most different between Mg and Mono for their expression in
TAMgs and TAMoMacs. This list includes six previously identified Mg-specific genes (Olfml3, Siglech, Tmem119, P2ry12,
Fcrls, and Sparc). We noted that cluster 6 showed the highest
expression of Mg-like genes among TAMoMacs (Figure 4B).
To examine the ontological relationships among the various
clusters within the identified ontological subsets (TAMoMacs
and TAMgs), and more specifically to examine whether cluster
6 cells are monocyte derived, we performed RNAvelocity analysis. This method analyzes the balance between production of
spliced mRNA from unspliced mRNA and mRNA degradation
to estimate the rate and direction of change of the entire transcriptome during a dynamic process such as cellular differentiation (La Manno et al., 2018). For this analysis, we used Mono in
the brain for cluster 3 (instead of circulating Mono) to more accurately examine the differentiation trajectory within the tumorbearing brain tissue. The results suggest that Mono of cluster 3
progressively differentiate into macrophages of clusters 8 and
1, followed by Mg-like cells of cluster 6 (Figures 4C and S2C).
However, RNAvelocity analysis was unable to establish a lineage
relationship between Mg and TAMg (Figure S2C). Pathway analysis of differentially expressed genes in TAMg versus Mg
(described further in later sections), showed higher metabolic activity, proliferation, and protein translation in TAMg. This violates
the basic assumption made in RNAvelocity that rate of splicing
and degradation are the same in all cells analyzed, which may
underlie the inability of this approach to establish a relationship
between Mg and TAMg.

(F) Violin plots (left graph) from scRNA-seq data showing lower Siglech and higher Clec12a by TAMoMacs. RNAscope in situ (micrograph, middle) with Siglech
(black) and Clec12 (red) probes of tumor tissue shows predominant mutually exclusive detection of each within cells. Student’s t test. n = 3 animals. Results are
expressed as mean ± SEM. *p % 0.05, **p % 0.01. Field: 3,190 3 1,974 mm. Scale bar: 50 mM.
(G) Heatmaps of TAMs showing TAMoMacs have higher expression than TAMgs of genes associated with antigen presentation, interferon signaling, and
activation of IRF by cytosolic recognition receptors.
See also Figures S2 and S4.
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Next, we sought to validate the aforementioned markers of
ontogeny identified by computational analyses. Among the
Mg-associated genes identified earlier, Siglech and Ttr displayed the lowest expression in TAMoMacs (Figure 4D). However, Ttr is also expressed by neurons (Li et al., 2011). Among the
Mono-associated genes, Clec12a displayed significant expression in all TAMoMac clusters, including cluster 6, which generally
expresses low levels of other Mono markers (Figure 4D). We validated some of these Mg- and Mono-specific genes by performing qRT-PCR on CD11b+CD45hiLy6GLy6chi cells (predicted to
contain cluster 8) and CD11b+CD45hiLy6GLy6clo cells (predicted to contain clusters 1 and 6) isolated from the cerebellum
of tumor-harboring mice. Consistent with scRNA-seq predictions, Fcrls is higher in Ly6clo cells, whereas levels of P2ry12
and Tmem119 were not significantly different between the two
isolated fractions (Figure 4E). Likewise, we confirmed lower
expression of Ccr2 and Clec4a3 in Ly6clo cells. qRT-PCR comparisons between these Ly6chi and Ly6clo populations and
CD11b+CD45lo (likely representing Mg) show Fcrls, P2ry12,
Siglech, and Tmem119 are highest in this population, as expected (Figure S2D).
We selected Siglech and Clec12a for validation as markers for
Mg and Mono origin, respectively, in SHH-MB. Given the vagaries of antibody-based detection, we used RNAscope in situ
analysis, which confirmed expression of Siglech and Clec12a
in tumor tissue. As predicted, Siglech, but not Clec12a, was expressed in Mg of the normal cerebellum (Figure S2E). Both
markers were only expressed in Iba1-positive cells in the tumor,
confirming their specific expression in macrophages. Clec12apositive cells were scattered throughout the tumor tissue, with
a somewhat higher concentration around the vasculature. Dual
staining showed a largely mutually exclusive pattern of expression of these markers in most macrophages in the tumor (Figure 4F). Altogether, our findings suggest that the combination
of staining for Clec12a and Siglech RNA can reliably distinguish
the two major ontological brain macrophage subsets in which
Siglech+Clec12a cells represent Mg or TAMg and Siglech
Clec12a+ cells represent monocyte-derived cells in the brain.
Ontogeny and microenvironment influence TAM gene
expression
Having established distinct ontology, we next analyzed the gene
expression pattern of TAMg and TAMoMac subpopulations to
gain insight into potential functional differences. Ingenuity
Pathway Analysis (IPA) showed that TAMoMacs are enriched
for pathways associated with antigen presentation, interferon
signaling, and activation of interferon regulatory factors (IRFs)
downstream of cytosolic pattern-recognition receptors (Figure 4G). The top 20 distinguishing genes among TAMoMac clusters (clusters 1, 6, and 8) and their Mono precursor (cluster 3)
showed enrichment for genes associated with antigen presentation in cluster 1 and interferon-signaling-associated genes in
cluster 8 (Figure S3A). Consistent with our previously described
findings, cells of cluster 6 were enriched for Mg-associated
genes. In addition, cluster 6 cells had higher expression of genes
associated with phagocytosis, such as Gas6, suggesting that
maturing TAMoMacs begin to adopt functions associated with
tissue macrophages (Figure S3A). Finally, Mono comprising
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cluster 3 were enriched for genes and pathways associated
with cellular migration, proliferation, and differentiation. We identified high expression of several S100 genes that are calciumbinding cytosolic proteins that are highly expressed in Mono
and neutrophils, are essential to their transmigration, and are
downregulated in Mono once they differentiate (Xia et al.,
2018). Altogether, these findings suggest an immunoregulatory
role of TAMoMacs.
TAMg subpopulations displayed downregulation of several
Mg-associated markers, such as Csf1r, P2ry12, Cx3cr1, and
Tmem119 (Figure S3B). The top 20 distinguishing genes among
Mg and TAMg (clusters 2 and 4) showed enrichment for genes
associated with antigen presentation in cluster 2 and genes
involved in cell cycling in cluster 4 (Figures S3B and S3C). IPA
showed that both TAMg subpopulations are more metabolically
active, with higher expression of oxidative phosphorylation
genes compared with homeostatic Mg. Cluster 2 had significantly higher expression of many ribosomal genes in the EIF2
signaling pathway, which is associated with activation of Mg
(Cabilly et al., 2012; Ryan et al., 2020). Cluster 4 showed enrichment of genes associated with cycle cycling, particularly through
the G2/M checkpoint, suggesting that they are more highly proliferative than resident Mg. These findings together suggest that
TAMg is more activated and proliferative than resident Mg.
A hallmark of embryonic precursor-derived tissue macrophages, such as Mg, is their ability to maintain their local population size by proliferation. In contrast, monocyte-derived macrophages are generally considered non-proliferative (Röszer,
2018). Consistent with this notion, we found that cluster 4 enriched for mitosis-associated genes compared with not just
TAMg subclusters but also all TAMoMac subclusters (data not
shown). This also suggests that Mg may be induced to proliferate
in the presence of a tumor.
We additionally analyzed the dataset using known markers for
inflammatory (interferon gamma [IFNg] and lipopolysaccharide
[LPS]-induced pathways) and anti-inflammatory (glucocorticoid,
transforming growth factor b [TGF-b], and interleukin [IL]-4 pathways) myeloid cells (Figure S4A). Mono and TAMoMacs clusters
6 and 8 have higher expression of several anti-inflammatory
markers that are lost in TAMoMac cluster 1. Homeostatic Mg
have higher expression of two markers of anti-inflammation,
Adora3 and Tgfbr2, that are decreased in TAMgs. Cluster 3
and 8 TAMoMacs have higher expression of several genes associated with inflammation (Figure S4B), thus showing that cells of
the same cluster can have increased expression of both inflammatory and anti-inflammatory genes in comparison to other cell
clusters. An interesting observation was higher expression of
Trem2 (triggering the receptor expressed on myeloid cells) and
Apoe (apolipoprotein E) in both TAMgs and TAMoMacs
compared with homeostatic Mg and peripheral Mono (Figure S4C). These two genes have been previously associated
with activated Mg in neurodegenerative pathologies such as
amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer
disease (Krasemann et al., 2017). This may indicate some degree
of functional overlap of pathologically activated Mg in neurodegenerative diseases and tumors.
To examine the relationship between TAMs and homeostatic
brain myeloid cells, we compared our data with a recently
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Figure 5. The composition of tumor-associated macrophages varies with treatment modality
(A) Immunohistochemical staining with F4/80 shows a dramatic increase in macrophages with radiation therapy. Student’s t test. n = 3 animals per treatment
group. Results are expressed as mean ± SEM. **p < 0.01. Field: 3,190 3 1,974 mm. Scale bar: 200 mM.
(B) UMAP plots of myeloid cells from treated tumors show higher microglia-derived and monocyte-derived macrophages with GDC-0449 and radiation treatment,
respectively.

(legend continued on next page)
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published scRNA-seq dataset of murine brain macrophages and
Mono (Li et al., 2019). Using the gene expression signatures of
Mg and Mono subsets identified by Li and colleagues as the
reference library for SingleR, we found good concordance between homeostatic Mg in the two independent datasets (Figure S4D) (Li et al., 2019). Highly proliferating TAMg cells (clusters
2 and 4, as well as a subset of cluster 6) in our data were identified as being most similar to S phase Mg in their dataset. Mono of
our cluster 3 and a subset of cluster 8 cells were annotated as
being closest to G2/M Mg in their dataset. Nonetheless, most
cells in our clusters 8, 1, and 6 were annotated to be most similar
to CD209a+ Mono in their dataset.
Finally, we wished to compare our scRNA-seq findings to
another brain tumor model, selecting scRNA-seq data from a
mouse model of an atypical teratoid rhabdoid tumor (ATRT)
(Melcher et al., 2020). Like MB, ATRT is an embryonal tumor.
We selected CD68+ cell clusters (macrophages) from the ATRT
dataset and annotated these clusters with SingleR, using our dataset as the reference library (Figure S4E). This approach identified cluster 4 in ATRT as Mg and composed of cells that were
similar to MB TAMg (clusters 2 and 4). Most monocyte-derived
macrophages in ATRT resembled cells of MB TAMoMac clusters
8 and 1. These findings support the existence of ontologically and
functionally similar TAMs in two embryonal brain tumor models.
Treatment modality alters TAM composition in SHH-MB
There is a great deal of interest among oncologists and tumor immunologists in characterizing the intratumoral immune responses to radiation, chemotherapy, and molecular-targeted
therapy. The overarching goal is to identify opportunities to
combine existing treatments with emerging immunotherapeutic
approaches. However, almost nothing is known about how
TAMs respond to treatment in brain tumors, especially SHHMB. Hence, we next investigated TAM responses to two distinct
treatment modalities: SHH-pathway inhibitor GDC-0449 that is
currently in clinical trial and radiation that is a part of the current
standard of care for all MB subtypes.
We followed a previously published GDC-0449 treatment
regimen (4 days of twice-daily treatment at 100 mg/kg/dose)
that was shown to reduce proliferation (Ki67 staining, reduced
from 70% to 10%) and increase apoptosis (TUNEL staining,
increased from 3% to 8%) within tumors of the same SHH-MB
murine model (Romer et al., 2004). Importantly, these effects
were accompanied by a clear survival advantage in which all untreated mice died by 10 weeks of age, whereas 50% of treated
mice were still alive at 21 weeks of age (Romer et al., 2004). To
examine the impact of radiation therapy in Ptch1+/p53/ tumors, we performed MRI of mice before and after radiation to

Resource
determine the effects on tumor size, cell proliferation (Ki67+),
and apoptosis (caspase-3). 7-week-old tumor-bearing mice
were imaged at baseline and 5 days later to measure tumor
growth. Mice then received a single dose of 10 Gy radiation
and were re-imaged 5 days later to measure tumor response.
This analyses clearly showed significant reduction in tumor
size post-radiation (Figure S5A). Analyses of tumor samples
also showed significantly reduced cell proliferation (p % 0.05)
and increased apoptosis (p % 0.01) with radiation (Figure S5B).
Thus, both radiation and GDC-0449 therapy are associated with
tumor regression, reduced cell proliferation, and enhanced
apoptosis in murine SHH-MB.
Next, we examined TAMs in irradiated and GDC-0449-treated
tumor samples using immunohistochemical (IHC) staining with
F4/80, finding dramatic increase in TAM infiltration with radiation
(p % 0.01, Figure 5A). We then performed scRNA-seq on
CD11b+ myeloid cells isolated from tumor-harboring cerebellum
of mice receiving each of the two treatment modalities, radiation
or GDC-0449, and aggregated data from two samples of each
treatment with batch correction (Figure 5B). Using SingleR to
annotate cells, we found that radiation induces a larger relative
proportion of Mono recruitment compared with GDC-0449. We
also used gene signatures of the different myeloid cell clusters
identified in our previous analyses of untreated tumors as the
reference dataset for SingleR (Figures 5B and S5C). Clusters 0,
1, and 3 are Mono and monocyte-derived TAMs in treated
tumors that are similar to clusters 1, 6, and 8, respectively, in TAMoMacs of untreated tumors. Cluster 5 of treated tumors appears to contain macrophages, Mono, and neutrophils (Figures
5B and S5C). Clusters 2 and 6 of treated TAMs resemble those
of cluster 2 in untreated tumors. Cluster 4 of untreated tumors
is reduced after GDC-0449 treatment.
Using the ontological markers we previously identified, clusters 4, 2, and 6 were labeled as Mg derived in treated tumors
and displayed high expression of Siglech (Figure 5C). Likewise,
clusters 0, 1, 3, and 5 were annotated as Mono/macrophages
in treated tumors and showed higher expression of Clec12a (Figure 5C). We also performed in situ hybridization with Siglech and
Clec12a probes on tumor tissue to confirm the scRNA-seq findings of radiation-induced enhancement of monocyte-derived
TAMs (Figure 5C) and quantified the probe staining (Figure S5D).
Because TAMoMacs were significantly increased with radiation, we examined the gene expression profile of TAMoMac clusters after radiation therapy. Clusters 3 and 5 showed significant
enhancement for pathways related to cell adhesion, diapedesis,
and IL-10 signaling (Figure 5D). Enrichment of adhesion and diapedesis pathways and high levels of Ly6c2 and Ccr2 (Figure 5E)
support the notion that these cells are newly recruited from

(C) RNAscope in situ (micrograph, right) with Siglech (black) and Clec12 (red) probes show the large increase in Clec12a-expressing, monocyte-derived macrophages with radiation that is consistent with scRNA-seq data (UMAP, left). Scale bar: 50 mM.
(D) Heatmap of TAMs from irradiated tumors shows clusters 3 and 5 have higher expression of genes associated with migration of the cells from the vasculature
and IL-10 signaling.
(E) Distribution (UMAP, left) and expression (violin plot, right) of Ly6c2 and Ccr2 show high levels in monocyte-derived clusters that accumulate after radiation.
(F) T cell proliferation assay shows Cd11b+Cd45hiLy6GLy6chi, but not Cd11b+Cd45hiLy6GLy6clo, from irradiated Ccr2WT tumors suppresses proliferation of
CD3/CD28-stimulated splenic CD8+ cells. The x axis shows carboxyfluorescein succinimidyl ester (CFSE)-associated fluorescence in CD8+ T cells. Student’s t
test. n = 3 (triplicate samples from one mouse). An additional two mice were analyzed to confirm differences in suppression of T cell proliferation between the two
cell types. Results are expressed as mean ± SEM. ***p < 0.001.
See also Figure S5.
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circulating Mono. IL-10 signaling in myeloid cells is frequently
associated with an immunosuppressive phenotype (Avdic
et al., 2013; Mittal et al., 2015). Hence, we examined immunemodulatory properties of radiation-induced, monocyte-derived
cells by performing an in vitro T cell proliferation assay. We relied
on a previously published flow-cytometry-based method of
identifying monocyte-derived macrophages from Mg based on
their higher expression of CD45 (Crotti and Ransohoff, 2016;
Lewis et al., 2014). We isolated CD11b+CD45hiLy6GLy6chi cells
(enriched for Ly6c-high TAMoMacs) and CD11b+CD45hi
Ly6GLy6clo cells (enriched for Ly6c-low TAMoMacs) (Figure S5E) from cerebella of irradiated tumor-bearing mice and
co-cultured them with splenic T cells stimulated with anti-CD3/
CD28. Remarkably, CD8+ T cell proliferation was significantly
inhibited by CD11b+CD45hiLy6GLy6chi cells, but not CD11b+
CD45hiLy6GLy6clo cells (Figure 5F). CD11b+CD45lo cells that
correspond to TAMg also did not inhibit T cell proliferation (Figure S5F). Altogether, these findings show accumulation of a
monocyte-derived immunosuppressive population with radiation, but not molecular-targeted therapy.
Reducing monocyte-derived TAMs promotes neutrophil
and CD8 T cell accumulation in irradiated tumors
Given the immunosuppressive signature of the Ly6c2+/Ccr2+
monocyte-derived macrophages and their ability to suppress
T cell proliferation in vitro, we next sought to determine the impact
of reducing these cells on the overall tumor immune microenvironment. We attempted to reduce intratumoral Mono in our SHH-MB
model by breeding the Ptch1+/Tp53/ mice to the Ccr2/ mice
that are deficient in circulating Mono (Boring et al., 1997)
(Figure 6A) to generate Ptch1+/ p53/ Ccr2/ (henceforth
Ccr2KO). Tumor growth in these mice were similar to Ptch1+/
p53/ Ccr2 WT (henceforth Ccr2WT) (Figure S6A). We also did
not see a survival difference between Ccr2WT and Ccr2KO.
Mono deficiency in the absence of Ccr2 was reported to correlate
with reduced survival in a genetically distinct Smo mouse model of
SHH-MB (Maximov et al., 2019). SHH-MB tumor progression in
our Ptch1+/ p53/ model is far more aggressive than the Smo
model used by Maximov and colleagues, which may underlie
this discrepant observation (Maximov et al., 2019). Nonetheless,
we found that Ccr2KO mice are similarly responsive to radiation
(average of 25% tumor volume reduction) in comparison to
Ccr2WT (average of 20% volume reduction) (Figure S6A).
Flow cytometry showed a significantly lower percentage, but
not depletion, of cerebellar CD45+CD11b+Ly6chi cells in Ccr2KO
compared with Ccr2WT mice (Figure 6B). This is consistent with
prior reports that Mono recruitment to the tumor is not exclusively Ccr2 dependent (Bennett et al., 2018). We measured absolute quantities of cells and observed a trend of decreased
CD11b+CD45hiLy6GLy6chi and CD11b+CD45hiLy6GLy6clo
cells with increased CD11b+CD45hiLy6G+ neutrophils cells per
cubic millimeter of tumor (Figure S6B).
Next, we performed scRNA-seq on three samples each of irradiated Ccr2WT and Ccr2KO to study changes in the composition
of immune infiltrates upon Mono deficiency in SHH-MB (Figure 6C). For sequencing, some samples were enriched for
CD11b+ and some were enriched for CD45+ cells. To quantify
the proportion of major immune cell types, we compared

scRNA-seq of CD45+-enriched cells from a pair of Ccr2WT
and Ccr2KO. As expected, tumor-bearing Ccr2KO cerebella
had reduced accumulation of Mono and macrophages (23% in
Ccr2KO and 65% in Ccr2WT) (Figure 6C). Consistent with this,
Clec12a-expressing TAMoMacs were reduced in Ccr2KO (Figures 6D, 5C, and S6C). We found no differences in the accumulation of suppressive Foxp3-expressing regulatory T cells (Tregs)
(Figure S6D). Strikingly, more than 50% of infiltrating myeloid
cells in irradiated Ccr2KO cerebella were composed of neutrophils. We confirmed this in the tumor microenvironment via
IHC with anti-Ly6G antibodies, finding a nearly 8-fold increase
in neutrophil infiltration of Ccr2KO tumors (Figure 6E). Compared
with circulating neutrophils and neutrophils that infiltrate Ccr2WT
tumor-harboring cerebella, we found that tumor-associated neutrophils (TANs) in Ccr2KO expressed higher levels of genes
associated with IL-10 signaling (Figure S6E). Hence, these
TANs may be immunoregulatory, akin to previously described
neutrophilic MDSCs (myeloid-derived suppressor cells) (Gabrilovich and Nagaraj, 2009). Finally, we examined the frequency of
CD8 T cells, finding a nearly 5-fold increase in CD8 T cell infiltration within the tumors of Ccr2KO mice (Figure 6F). Despite the
accumulation of neutrophils/granulocytic MDSCs, CD8+ T cell
increases within tumors in Ccr2KO suggests that perhaps monocyte-derived macrophages or monocytic MDSCs are more
immunosuppressive compared with neutrophils/granulocytic
MDSCs in our system.
Altogether, these data show accumulation of an immunosuppressive monocyte-derived macrophage upon radiation therapy
in SHH-MB. Reducing this population appeared to engender an
immunostimulatory tumor microenvironment marked by
increased CD8 T cell infiltration. However, further immune responses may be restrained by the accumulation of immunosuppressive neutrophils.
DISCUSSION
TAMs play an important role in the pathobiology of solid tumors.
Pro-inflammatory TAMs support, whereas anti-inflammatory
TAMs suppress, anti-tumor immune responses. TAMs can also
produce factors that promote tumor growth, angiogenesis, and
metastasis (Lee et al., 2018; Maximov et al., 2019). Studies in
many types of solid tumors show that TAMs are heterogeneous
and their composition varies among tumors (Alshetaiwi et al.,
2020; Gubin et al., 2018; Melcher et al., 2020). Despite increasing
interest in TAMs as therapeutic targets, most studies have been
performed on tumors outside the brain. The brain microenvironment is unique from an immunological perspective; hence, findings from other solid tumors may not be fully applicable to TAMs
in brain tumors. Furthermore, the few TAM studies in brain
mostly relate to gliomas and one recent study employing single-cell analysis on atypical teratoid rhabdoid tumors (Melcher
et al., 2020), leaving a major gap in our understanding of these
cells in other types of brain tumors. Hence, the scRNA-seq of
murine SHH-MB generated in this study will be a useful resource
for the larger neuro-oncology community. Another resource
described here is the OpenPBTA dataset of human MB RNAseq, which is newly established, well curated, and publicly available. The new insight into TAMs described here highlights the
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Figure 6. Decreasing monocyte-derived macrophages enhances CD8 T cell and neutrophil infiltration
(A) Ptch1+/Tp53/ (Ccr2WT) and Ccr2/ mice were bred to produce Ptch1+/Tp53/Ccr2/ (Ccr2KO) mice.
(B) Flow cytometry of cerebellar myeloid cells showing reduced Cd11b+Cd45hiLy6GLy6chi cells in irradiated Ccr2KO mice. Student’s t test. N = 8 Ccr2WT mice,
6 Ccr2KO mice. Results are expressed as mean ± SEM. *p % 0.05.
(C) UMAP plots of scRNA-seq of cerebellar leukocytes from irradiated Ccr2WT and Ccr2KO showing reduced monocyte-derived macrophages and enhanced
neutrophils in the latter.
(D) RNAscope in situ with Siglech (black) and Clec12 (red) probes showing reduced accumulation of Clec12a-positive cells in irradiated Ccr2KO in comparison to
Ccr2WT of Figure 5C. Scale bar: 50 mM.
(E and F) Immunohistochemical staining with Ly6G (E) and CD8 (F) antibody showing an increase in neutrophil and CD8+ T cells in irradiated tumors from Ccr2KO
(right plots) compared with Ccr2WT (left plots). Student’s t test. n = 3 animals per treatment group. Results are expressed as mean ± SEM. **p % 0.01, ***p %
0.001. Field: 3,190 3 1,974 mm. Scale bar: 200 mM.
See also Figure S6.

value of these datasets in understanding the immune
microenvironment of SHH-MB.
Our findings regarding TAM ontogeny align with previous notions regarding dual origins of brain tumor macrophages and
extend these by identifying markers of ontologically distinct
TAMs. Nonetheless, further studies are needed to confirm whether
Siglech and Clec12a mark Mg and Mono origins of TAMs in other
types of brain tumors. Our analyses of monocyte-derived TAMs
identified the distinct maturation states as Mono differentiate
into TAMs in the brain. Notably, these monocyte-derived cells
begin to acquire expression of genes typically associated with
Mg, underscoring the impact of the brain microenvironment on
macrophage gene expression. An intriguing observation relates
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to the proliferative nature of microglia-derived TAMs, but not
monocyte-derived TAMs. This is consistent with previous observations that tissue macrophages derived from embryonic precursors, like Mg, have significantly higher proliferative capacity
compared with monocyte-derived macrophages (Röszer, 2018).
However, why TAMg is more proliferative than its precursor Mg
is unclear at present and warrants further investigation.
Our findings regarding the impact of treatment modality on TAM
heterogeneity are particularly interesting, with important implications in immunotherapy. GDC-0449 and radiation induced distinct
changes in TAM composition, and in this study, we mostly focus on
radiation that induced a large and distinct population of monocytederived TAMs with immunosuppressive hallmarks. Nonetheless,
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changes induced upon GDC-0449 treatments are significant and
might inform future attempts to combine immunotherapy with molecular-targeted approaches. Radiation therapy may induce
release of damage-associated molecular patterns from cancer
cells that can recruit Mono via the chemokine CCL2, which may
explain the selective recruitment of TAMoMacs with radiation,
but not GDC-0449 therapy (Liang et al., 2017).
The dramatic infiltration of neutrophils post-radiation in the
absence of TAMoMacs suggest an inhibitory role of TAMoMacs
on neutrophil infiltration. Perhaps a more important question is
whether these neutrophils promote or inhibit anti-tumor immune responses. The depletion in Ccr2 leading to a compensatory increase
in neutrophils has been previously shown in a few non-CNS tumors
(Nywening et al., 2018; Pahler et al., 2008; Sawanobori et al., 2008).
The correlation between TAMoMacs and neutrophil infiltration is
highly intriguing, but its mechanistic basis and functional implications remain unclear. Indeed, the function of TANs remains unclear,
especially in brain tumors, with evidence reported for both anti- and
pro-tumor activity (Piccard et al., 2012; Powell and Huttenlocher,
2016; Takeshima et al., 2016). If these neutrophils in SHH-MB are
immunosuppressive, perhaps dual depletion of neutrophils and
monocyte-derived macrophages may engender a more robust
adaptive immune response with radiation therapy.
In summary, we present comprehensive myeloid-focused
analysis of bulk RNA-seq of human MB and scRNA-seq of murine SHH-MB and demonstrate the value of this dataset as a
discovery tool.
STAR+METHODS

ACKNOWLEDGMENTS
This work was supported by National Institutes of Health NIAID-KO8AI106953,
Burroughs Wellcome Fund CAMS award, and American Society of Hematology scholar award (to M.H.); Training Program in Neurodevelopmental Disabilities T32NS007413, Child Neurologist Career Development Training Program
1K12NS098482, Wylie’s Day Foundation, Musella Foundation, and Gray Matters Foundation (to M.T.D.); Alex’s Lemonade Stand Foundation Young Investigator and Catalyst Awards (to J.L.R.); and Alex’s Lemonade Stand Foundation (CCDL). We thank Drs. Weixia Liu and Stephen Pickup for their
assistance with MRI, Dr. Khayrullo Shoniyozov and Denisa Goia for their assistance with radiation, Drs. Jay Storm and Adam Resnick for their dedication to
the generation of human patient date used in the OpenPBTA project, Dr. Mateusz Koptyra for his helpful suggestions, and Dr. Chi Van Dang for his invaluable insight.
AUTHOR CONTRIBUTIONS
Conceptualization and methodology, M.T.D., M.H., P.Y., Z.A., T.K.J.T., L.Z.,
I.W.K., and S.D.; analysis, M.T.D., M.H., M.V.G., K.S.G., K.S.R., P.R., J.L.R.,
D.M., J.N.T., J.A.S., C.S.G., C.S., F.M., and H.H.; investigation, M.T.D.,
M.H., and M.V.G.; resources, M.H., M.T.D., M.V.G., and T.C.; data curation,
M.T.D., M.H., and M.V.G.; writing, M.T.D. and M.H.; editing, M.T.D., M.V.G.,
and M.H.; supervision, M.T.D. and M.H.; project administration, M.H.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: June 1, 2020
Revised: January 13, 2021
Accepted: March 9, 2021
Published: March 30, 2021
REFERENCES

Detailed methods are provided in the online version of this paper
and include the following:
d
d

d

d

d

KEY RESOURCES TABLE
RESOURCE AVAILABILITY
B Lead contact
B Materials availability
B Data and code availability
EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Human samples
B Animals
METHOD DETAILS
B RNaseq analysis of human tumors
B Magnetic resonance imaging and analysis of tumor
volume
B scRNA-sequencing and analysis
B Immunohistochemistry
B RNA in situ hybridization
B Flow cytometry
B RNA isolation and qPCR analysis for gene for gene
expression
B T cell suppression assay
QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
celrep.2021.108917.

Alshetaiwi, H., Pervolarakis, N., McIntyre, L.L., Ma, D., Nguyen, Q., Rath, J.A.,
Nee, K., Hernandez, G., Evans, K., Torosian, L., et al. (2020). Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell
transcriptomics. Sci. Immunol. 5, eaay6017.
Aran, D., Hu, Z., and Butte, A.J. (2017). xCell: digitally portraying the tissue
cellular heterogeneity landscape. Genome Biol. 18, 220.
Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi,
R.P., Wolters, P.J., Abate, A.R., et al. (2019). Reference-based analysis of lung
single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172.
Avdic, S., Cao, J.Z., McSharry, B.P., Clancy, L.E., Brown, R., Steain, M., Gottlieb, D.J., Abendroth, A., and Slobedman, B. (2013). Human cytomegalovirus
interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to
repress host immune responses. J. Virol. 87, 10273–10282.
Becht, E., Giraldo, N.A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F.,
Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W.H., and de Reyniès, A. (2016). Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17,
218.
Bennett, M.L., Bennett, F.C., Liddelow, S.A., Ajami, B., Zamanian, J.L., Fernhoff, N.B., Mulinyawe, S.B., Bohlen, C.J., Adil, A., Tucker, A., et al. (2016). New
tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad.
Sci. USA 113, E1738–E1746.
Bennett, F.C., Bennett, M.L., Yaqoob, F., Mulinyawe, S.B., Grant, G.A., Hayden Gephart, M., Plowey, E.D., and Barres, B.A. (2018). A Combination of
Ontogeny and CNS Environment Establishes Microglial Identity. Neuron 98,
1170–1183.e8.
Binnewies, M., Roberts, E.W., Kersten, K., Chan, V., Fearon, D.F., Merad, M.,
Coussens, L.M., Gabrilovich, D.I., Ostrand-Rosenberg, S., Hedrick, C.C., et al.

Cell Reports 34, 108917, March 30, 2021 13

ll
OPEN ACCESS

(2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550.
Boring, L., Gosling, J., Chensue, S.W., Kunkel, S.L., Farese, R.V., Jr., Broxmeyer, H.E., and Charo, I.F. (1997). Impaired monocyte migration and reduced
type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice.
J. Clin. Invest. 100, 2552–2561.

Resource
Haage, V., Semtner, M., Vidal, R.O., Hernandez, D.P., Pong, W.W., Chen, Z.,
Hambardzumyan, D., Magrini, V., Ly, A., Walker, J., et al. (2019). Comprehensive gene expression meta-analysis identifies signature genes that distinguish
microglia from peripheral monocytes/macrophages in health and glioma. Acta
Neuropathol. Commun. 7, 20.

Bouffet, E. (2021). Management of high-risk medulloblastoma. Neurochirurgie
67, 61–68.

Heng, T.S., and Painter, M.W.; Immunological Genome Project Consortium
(2008). The Immunological Genome Project: networks of gene expression in
immune cells. Nat. Immunol. 9, 1091–1094.

Bowman, R.L., Klemm, F., Akkari, L., Pyonteck, S.M., Sevenich, L., Quail, D.F.,
Dhara, S., Simpson, K., Gardner, E.E., Iacobuzio-Donahue, C.A., et al. (2016).
Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in
Brain Malignancies. Cell Rep. 17, 2445–2459.

Hovestadt, V., Smith, K.S., Bihannic, L., Filbin, M.G., Shaw, M.L., Baumgartner, A., DeWitt, J.C., Groves, A., Mayr, L., Weisman, H.R., et al. (2019).
Resolving medulloblastoma cellular architecture by single-cell genomics. Nature 572, 74–79.

Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420.

Konishi, H., Kobayashi, M., Kunisawa, T., Imai, K., Sayo, A., Malissen, B.,
Crocker, P.R., Sato, K., and Kiyama, H. (2017). Siglec-H is a microglia-specific
marker that discriminates microglia from CNS-associated macrophages and
CNS-infiltrating monocytes. Glia 65, 1927–1943.

Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P.M., Doykan, C.E., et al. (2014).
Identification of a unique TGF-b-dependent molecular and functional signature
in microglia. Nat. Neurosci. 17, 131–143.
Cabilly, Y., Barbi, M., Geva, M., Marom, L., Chetrit, D., Ehrlich, M., and ElroyStein, O. (2012). Poor cerebral inflammatory response in eIF2B knock-in mice:
implications for the aetiology of vanishing white matter disease. PLoS ONE 7,
e46715.
Chen, B., Khodadoust, M.S., Liu, C.L., Newman, A.M., and Alizadeh, A.A.
(2018). Profiling tumor infiltrating immune cells with CIBERSORT. Methods
Mol. Biol. 1711, 243–259.
Chung, W., Eum, H.H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H.S.,
Kim, S., Lee, J.E., Park, Y.H., et al. (2017). Single-cell RNA-seq enables
comprehensive tumour and immune cell profiling in primary breast cancer.
Nat. Commun. 8, 15081.
Crotti, A., and Ransohoff, R.M. (2016). Microglial Physiology and Pathophysiology: Insights from Genome-wide Transcriptional Profiling. Immunity 44,
505–515.
Dijkgraaf, G.J.P., Alicke, B., Weinmann, L., Januario, T., West, K., Modrusan,
Z., Burdick, D., Goldsmith, R., Robarge, K., Sutherlin, D., et al. (2011). Small
molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 71, 435–444.
FlowJoTM Software (2019). FlowJoTM Software (for Windows or for Mac) [software application], Version 9 (Becton, Dickinson and Company).
La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V.,
Lidschreiber, K., Kastriti, M.E., Lönnerberg, P., Furlan, A., et al. (2018). RNA velocity of single cells. Nature 560, 494–498.
Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as
regulators of the immune system. Nat. Rev. Immunol. 9, 162–174.
Gajjar, A., Stewart, C.F., Ellison, D.W., Kaste, S., Kun, L.E., Packer, R.J., Goldman, S., Chintagumpala, M., Wallace, D., Takebe, N., et al. (2013). Phase I
study of vismodegib in children with recurrent or refractory medulloblastoma:
a pediatric brain tumor consortium study. Clin. Cancer Res. 19, 6305–6312.
Ginhoux, F., Lim, S., Hoeffel, G., Low, D., and Huber, T. (2013). Origin and differentiation of microglia. Front. Cell. Neurosci. 7, 45.
, L., Higgins, K.M., and Scott, M.P. (1997). Altered
Goodrich, L.V., Milenkovic
neural cell fates and medulloblastoma in mouse patched mutants. Science
277, 1109–1113.
€ddemann, A. (2017). Tissue macrophages: heterogeneity
Gordon, S., and Plu
and functions. BMC Biol. 15, 53.
Guadagno, E., Presta, I., Maisano, D., Donato, A., Pirrone, C.K., Cardillo, G.,
Corrado, S.D., Mignogna, C., Mancuso, T., Donato, G., et al. (2018). Role of
Macrophages in Brain Tumor Growth and Progression. Int. J. Mol. Sci. 19,
1005.
Gubin, M.M., Esaulova, E., Ward, J.P., Malkova, O.N., Runci, D., Wong, P., Noguchi, T., Arthur, C.D., Meng, W., Alspach, E., et al. (2018). High-Dimensional
Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during
Successful Immune-Checkpoint Cancer Therapy. Cell 175, 1014–1030.e19.

14 Cell Reports 34, 108917, March 30, 2021

Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R.,
Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017). The TREM2-APOE
pathway drives the transcriptional phenotype of dysfunctional microglia in
neurodegenerative diseases. Immunity 47, 566–581.e9.
Lee, C., Lee, J., Choi, S.A., Kim, S.-K., Wang, K.-C., Park, S.-H., Kim, S.H.,
Lee, J.Y., and Phi, J.H. (2018). M1 macrophage recruitment correlates with
worse outcome in SHH Medulloblastomas. BMC Cancer 18, 535.
Lewis, N.D., Hill, J.D., Juchem, K.W., Stefanopoulos, D.E., and Modis, L.K.
(2014). RNA sequencing of microglia and monocyte-derived macrophages
from mice with experimental autoimmune encephalomyelitis illustrates a
changing phenotype with disease course. J. Neuroimmunol. 277, 26–38.
Li, X., Masliah, E., Reixach, N., and Buxbaum, J.N. (2011). Neuronal production of transthyretin in human and murine Alzheimer’s disease: is it protective?
J. Neurosci. 31, 12483–12490.
Li, Q., Cheng, Z., Zhou, L., Darmanis, S., Neff, N.F., Okamoto, J., Gulati, G.,
Bennett, M.L., Sun, L.O., Clarke, L.E., et al. (2019). Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA
Sequencing. Neuron 101, 207–223.e10.
Liang, H., Deng, L., Hou, Y., Meng, X., Huang, X., Rao, E., Zheng, W., Mauceri,
H., Mack, M., Xu, M., et al. (2017). Host STING-dependent MDSC mobilization
drives extrinsic radiation resistance. Nat. Commun. 8, 1736.
Margol, A.S., Robison, N.J., Gnanachandran, J., Hung, L.T., Kennedy, R.J.,
Vali, M., Dhall, G., Finlay, J.L., Erdreich-Epstein, A., Krieger, M.D., et al.
(2015). Tumor-associated macrophages in SHH subgroup of medulloblastomas. Clin. Cancer Res. 21, 1457–1465.
Maximov, V., Chen, Z., Wei, Y., Robinson, M.H., Herting, C.J., Shanmugam,
N.S., Rudneva, V.A., Goldsmith, K.C., MacDonald, T.J., Northcott, P.A.,
et al. (2019). Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nat. Commun. 10, 2410.
McKenzie, A.T., Wang, M., Hauberg, M.E., Fullard, J.F., Kozlenkov, A.,
Keenan, A., Hurd, Y.L., Dracheva, S., Casaccia, P., Roussos, P., and Zhang,
B. (2018). Brain Cell Type Specific Gene Expression and Co-expression
Network Architectures. Sci. Rep. 8, 8868.
Melcher, V., Graf, M., Interlandi, M., Moreno, N., de Faria, F.W., Kim, S.N., Kastrati, D., Korbanka, S., Alfert, A., Gerß, J., et al. (2020). Macrophage-tumor cell
interaction promotes ATRT progression and chemoresistance. Acta Neuropathol. 139, 913–936.
Mittal, S.K., Cho, K.-J., Ishido, S., and Roche, P.A. (2015). Interleukin 10 (IL10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS.
J. Biol. Chem. 290, 27158–27167.
€ller, S., Kohanbash, G., Liu, S.J., Alvarado, B., Carrera, D., Bhaduri, A.,
Mu
Watchmaker, P.B., Yagnik, G., Di Lullo, E., Malatesta, M., et al. (2017). Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis
for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 18, 234.

ll
Resource
Nywening, T.M., Belt, B.A., Cullinan, D.R., Panni, R.Z., Han, B.J., Sanford,
D.E., Jacobs, R.C., Ye, J., Patel, A.A., Gillanders, W.E., et al. (2018). Targeting
both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in
pancreatic ductal adenocarcinoma. Gut 67, 1112–1123.
Olingy, C.E., Dinh, H.Q., and Hedrick, C.C. (2019). Monocyte heterogeneity
and functions in cancer. J. Leukoc. Biol. 106, 309–322.
Pahler, J.C., Tazzyman, S., Erez, N., Chen, Y.-Y., Murdoch, C., Nozawa, H.,
Lewis, C.E., and Hanahan, D. (2008). Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10, 329–340.
Piccard, H., Muschel, R.J., and Opdenakker, G. (2012). On the dual roles and
polarized phenotypes of neutrophils in tumor development and progression.
Crit. Rev. Oncol. Hematol. 82, 296–309.
Powell, D.R., and Huttenlocher, A. (2016). Neutrophils in the Tumor Microenvironment. Trends Immunol. 37, 41–52.
Robinson, G.W., Orr, B.A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I.,
Packer, R.J., Goldman, S., Prados, M.D., Desjardins, A., et al. (2015). Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup
Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium
Studies PBTC-025B and PBTC-032. J. Clin. Oncol. 33, 2646–2654.
Robinson, G.W., Kaste, S.C., Chemaitilly, W., Bowers, D.C., Laughton, S.,
Smith, A., Gottardo, N.G., Partap, S., Bendel, A., Wright, K.D., et al. (2017).
Irreversible growth plate fusions in children with medulloblastoma treated
with a targeted hedgehog pathway inhibitor. Oncotarget 8, 69295–69302.
Romer, J.T., Kimura, H., Magdaleno, S., Sasai, K., Fuller, C., Baines, H., Connelly, M., Stewart, C.F., Gould, S., Rubin, L.L., and Curran, T. (2004). Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/)p53(/) mice. Cancer Cell 6, 229–240.
Röszer, T. (2018). Understanding the Biology of Self-Renewing Macrophages.
Cells 7, 103.
Ryan, S.K., Gonzalez, M.V., Garifallou, J.P., Bennett, F.C., Williams, K.S., Sotuyo, N.P., Mironets, E., Cook, K., Hakonarson, H., Anderson, S.A., and Jordan-Sciutto, K.L. (2020). Neuroinflammation and EIF2 Signaling Persist

OPEN ACCESS

despite Antiretroviral Treatment in an hiPSC Tri-culture Model of HIV Infection.
Stem Cell Reports 14, 703–716.
Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., and Regev, A. (2015). Spatial
reconstruction of single-cell gene expression data. Nat. Biotechnol. 33,
495–502.
Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J.E., Abe, J.,
Shono, Y., Kitabatake, M., Kakimi, K., Mukaida, N., and Matsushima, K. (2008).
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111, 5457–5466.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch,
T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an
open-source platform for biological-image analysis. Nat. Methods 9, 676–682.
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M.,
3rd, Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive
Integration of Single-Cell Data. Cell 177, 1888–1902.e21.
Takeshima, T., Pop, L.M., Laine, A., Iyengar, P., Vitetta, E.S., and Hannan, R.
(2016). Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. Proc. Natl. Acad. Sci. USA 113, 11300–
11305.
Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and
regulators of cell fate decisions are revealed by pseudotemporal ordering of
single cells. Nat. Biotechnol. 32, 381–386.
Wetmore, C., Eberhart, D.E., and Curran, T. (2001). Loss of p53 but not ARF
accelerates medulloblastoma in mice heterozygous for patched. Cancer
Res. 61, 513–516.
Xia, C., Braunstein, Z., Toomey, A.C., Zhong, J., and Rao, X. (2018). S100 Proteins As an Important Regulator of Macrophage Inflammation. Front. Immunol.
8, 1908.
Yushkevich, P.A., Piven, J., Hazlett, H.C., Smith, R.G., Ho, S., Gee, J.C., and
Gerig, G. (2006). User-guided 3D active contour segmentation of anatomical
structures: significantly improved efficiency and reliability. Neuroimage 31,
1116–1128.

Cell Reports 34, 108917, March 30, 2021 15

ll
OPEN ACCESS

Resource

STAR+METHODS
KEY RESOURCES TABLE

REAGENT or RESOURCE

SOURCE

IDENTIFIER

IbaI unconjugated antibody

Wako Chemicals

019-19741; RRID:AB_839504

F4/80 unconjugated antibody

Thermo Fisher Scientific

MF48000; RRID:AB_10376289

CD8 unconjugated antibody

Abcam

ab203035

Antibodies

Ly6G unconjugated antibody

StemCell Technologies

60031; RRID:AB_2877150

Caspase 3 unconjugated antibody

R&D Systems

AF835; RRID:AB_2243952

Ki67 unconjugated antibody

Abcam

ab16667; RRID:AB_302459

FoxP3 unconjugated antibody

eBioscience

14-5773-95; RRID:AB_2865134

Anti-rabbit biotinylated secondary antibody

Vector Labs

BA-1000; RRID:AB_2313606

Anti-rat biotinylated secondary antibody

Vector Labs

BA-4001; RRID:AB_10015300

BV510 CD45 anti-mouse antibody

BioLegend

103138; RRID:AB_2563061

PE-Cy7 Cd11b anti-mouse antibody

Fisher Scientific

25-0112-82; RRID:AB_469588

Ly-6C fluorescent AF488 Ly-6C anti-mouse
antibody

BioLegend

128021; RRID:AB_10640820

PerCp/Cy5.5 Ly-6G anti-mouse antibody

BioLegend

127615; RRID:AB_1877272

AF594 CD8a anti-mouse antibody

BioLegend

100758; RRID:AB_2563237

GDC-0449

Chemitek

CT-G0449

Methylcellulose

Sigma

M0512

Tween 80

Sigma

P1754

Chemicals, peptides, and recombinant proteins

Isofluorane

Sigma

792632

Percoll

Sigma

17-0891-02

CD11b+ magnetic microbeads

Miltenyi Biotec

130-092-636

CD45+ magnetic microbeads

Miltenyi Biotec

130-052-301

LS columns

Miltenyi Biotec

130-042-401

ACK lysing buffer

ThermoFisher

A1049201

Chromium Single Cell 30 Reagent kit v2

10xGenomics

120234

Chromium i7 Sample Index Kit

10xGenomics

PN-120262

CFSE

Life Technologies

C34554

Avidin/biotin ABC complex

Vector Labs

PK-6102; RRID:AB_2336821

DAB substrate chromogen

DAKO

SK-4100; RRID:AB_2336382

Mm-Siglech CISH probe

Advanced Cell Diagnostics

ref#432678

Mm-Clec12a CISH probe

Advanced Cell Diagnostics

ref#514358

Mm-Clec12a-C2 CISH probe

Advanced Cell Diagnostics

ref#514358-C2

RNAscope 2.5 LS Duplex Reagent Kit

Advanced Cell Diagnostics

32240

Bond Refine staining kit

Leica Biosystems

DS9800

Collagenase B, from Clostridium histolyticum

Sigma-Aldrich

11088815001

DNaseI

Sigma-Aldrich

D4527-200KU

CD16/32 Fc Block

BD Biosciences

553142; RRID:AB_394657

aCD3/28 beads

ThermoFisher Scientific

11131D

Recombinant human IL-2

Peprotech, Inc.

200-02

Hprt Taqman Q-PCR probe

ThermoFisher Scientific

Mm03024075_m1

Clec12a Taqman Q-PCR probe

ThermoFisher Scientific

Mm00624579_m1

Clec4a3 Taqman Q-PCR probe

ThermoFisher Scientific

Mm00462705_m1

Ccr2 Taqman Q-PCR probe

ThermoFisher Scientific

Mm04207877_m1
(Continued on next page)

e1 Cell Reports 34, 108917, March 30, 2021

ll
OPEN ACCESS

Resource
Continued
REAGENT or RESOURCE

SOURCE

IDENTIFIER

Fcrls Taqman Q-PCR probe

ThermoFisher Scientific

Mm00472833_m1

P2ry12 Taqman Q-PCR probe

ThermoFisher Scientific

Mm00446026_m1

Tmem119 Taqman Q-PCR probe

ThermoFisher Scientific

Mm00525305_m1

Siglech Taqman Q-PCR probe

ThermoFisher Scientific

Mm00618627_m1

CD11b magnetic microbeads, human/mouse

Miltenyi Biotec

130-093-636

CD45 magnetic microbeads, mouse

Miltenyi Biotec

130-052-301

LS columns

Miltenyi Biotec

130-042-401

Myelin Removal Beads II, human, mouse, rat

Miltenyi Biotec

130-096-733

CountBright Absolute Counting Beads

ThermoFisher Scientific

C36950

Pan T cell isolation kit II

Miltenyi Biotec

130-095-130

Mouse: Ptch+/

Jackson Laboratory

030494

Mouse: Ccr2/

Jackson Laboratory

004999

Mouse: Tp53/

Jackson Laboratory

002101

This paper

GEO: GSE166691

Seurat package (v.3.0)
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FlowJoTM Software, 2019
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ImageJ
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Uploaded data
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RESOURCE AVAILABILITY
Lead contact
Further information and request for resources and reagents should be directed to and will be fulfilled by the lead contact, Malay
Haldar (mhaldar@pennmedicine.upenn.edu)
Materials availability
This study did not generate new unique reagents.
Data and code availability
The accession number for all new scRNA-Seq data reported in this paper is [GEO: GSE166691].
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human samples
Brain tumor samples were collected for the Pediatric Brain Tumor Atlas, a collaborative effort by Children’s Brain Tumor Tissue
Consortium and Pacific Pediatric Neuro-Oncology Consortium with patients and their families. Data in this atlas include matched
tumor/normal tissue, whole genome sequencing, exome sequencing, and RNA-seq, proteomics, and miRNA along with longitudinal
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clinical data, pathology reports, and imaging data. A manuscript detailing the establishment of this dataset is currently in preparation
and can be found at
https://alexslemonade.github.io/OpenPBTA-manuscript/.
Animals
Three genetically engineered models purchased from Jackson Laboratory were used: Ptch+/ (stock no. 030494), Tp53/ (stock no.
002101), Ccr2/ (004999). Ptch1+/-Tp53/ mice were bred and Ccr2/ genotyping was performed as previously reported (Boring
et al., 1997; Wetmore et al., 2001). Both males and females of both Ptch1+/Tp53/ and Ptch1+/-Tp53/Ccr2/ were used for this
study. Mice were bred and maintained in specific pathogen free facilities at the University of Pennsylvania. Mice were group-housed
(21 C; 12h:12h light: dark cycle) and given ad libitum access to standard rodent diet. Mice used for source of homeostatic microglia
and peripheral myeloid cells were 2 weeks old. Mice for all other experiments were 7 to 8 weeks old. All animal procedures were
conducted according to National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee
at the University of Pennsylvania.
Mice were treated with SMO inhibitor, GDC-0449 (Chemitek, suspended in 0.5% methylcellulose and 0.2% Tween 80) at a dose of
100mg/kg twice a day for 4 days. Brains were resected and analyzed 12 hours after the 8th dose.
Radiation treatment was completed on a Small Animal Radiation Research Platform that delivers photon radiation with CT-guided
location. Mice were anesthesized with 2% isoflurane in a carrier gas of medical grade air utilizing an induction chamber connected to
anesthesia machine (Matrx). Once the mouse reached the desired plane of anesthesia (2 minutes), the animal was placed on the
SARRP’s (Xstrahl Life Sciences) irradiation platform with the nose of the mouse in a nosecone where flow of administered isoflurane
(maintained at 2%) was remotely controlled using Somnosuite (Kent Scientific) anesthesia system. The mouse tumor was targeted
manually with the help of onboard positioning lasers of the SARRP. 10Gy doses were delivered using 10 mm diameter collimated
beam of X-rays with tube potential of 220kVp, 13mA current and dose rate of 2Gy/min. Mice that were used for scRNA-Seq
received 3 doses of 10Gy radiation on consecutive days. Whole cerebellum was resected for TAM isolation 5 days after the last
dose of radiation. Tissues from irradiated mice for all other experiments received 1 dose of 10Gy radiation and tissues were analyzed
5 days after radiation.
METHOD DETAILS
RNaseq analysis of human tumors
Collapsed RNA-Seq data from 123 human medulloblastoma tissues were obtained through data release V13 of the OpenPBTA
project (https://github.com/AlexsLemonade/OpenPBTA-analysis), a global open science collaborative efforts of the Children’s Brain
Tumor Tissue Consortium, Pediatric Neuro-oncology Consortium, Alex’s Lemonade Stand Foundation’s Childhood Cancer Data
Lab, and the Center for Data-Driven Discovery in Biomedicine at the Children’s Hospital of Philadelphia.
Microenvironment Cell Populations-counter (MCP-Counter), xCell, and CIBERSORT methods from the R package immunedeconv
(Becht et al., 2016; Chen et al., 2018; Aran et al., 2017) were used to deconvolute the tumor microenvironment of 123 human medulloblastoma RNA-Seq samples consisting of four molecular subtypes i.e., Group 3 (n = 15), WNT (n = 11), Group 4 (n = 67) and SHH (n =
31). Analysis represents cell type enrichment as abundance scores that are correlated to actual cell type proportions. To visualize the
subtype specific enrichment, we created a heatmap of average immune scores per cell type across each molecular subtype.
BRETIGEA (McKenzie et al., 2018) method was used to find surrogate proportion variables (SPV) of brain cells astrocytes,
endothelial cells, microglia, neurons, oligodendrocytes, and oligodendrocyte precursor cells, derived from each of human, mice,
and combination human/mouse datasets. In addition to that, we added monocyte marker genes from prior published work and
monocyte marker genes from xCell (Aran et al., 2017) to calculate surrogate proportion variables for monocyte cell types in brain
samples. The results should be considered as preliminary data which needs further validation by correlating SPV to true monocyte
cell proportions in control datasets. We ran function findCells() using SVD method to calculate SPVs and all 1000 marker genes for
brain cell types provided in BRETIGEA package along with 317 genes for monocyte. All cell type SPVs were then plotted for each
sample as stacked bar plots.
Magnetic resonance imaging and analysis of tumor volume
Images were obtained with a 9.4 Tesla 31 cm horizontal bore MR System using ParaVision acquisition software. During the scan the
mouse laid in a prone position within the coil. Body temperature was maintained at 37 C. Mice were anesthetized throughout the
experiment by a gaseous mixture of isoflurane and oxygen. The respiration rate was continuously measured using the Small Animal
Monitoring and Gating System (SA Instrument). After obtaining a series of localizers, contiguous image slices capturing the entire
brain volume were obtained in the coronal directions. Fifteen slices of 0.5 mm thickness were acquired inter-leaved with a FOV of
20 3 20 mm. Other conditions were as follow: echo time 2ms, repetition time 200ms, averages of 1, repetitions 1. The time of acquisition was approximately 5 minutes. Volumetric analysis was carried out using ITK-SNAP (Yushkevich et al., 2006; http://www.
itksnap.org/pmwiki/pmwiki.php).
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scRNA-sequencing and analysis
Whole cerebellar tissue were mechanically homogenized in RPMI medium. Immune cells were purified using a 70/30 Percoll (Sigma
Aldrich, 17-0891-02) gradient spun for 30 minutes at 500G. Cells at the interface were collected and further purified with CD11b+
magnetic microbeads (Miltenyi Biotec, 130-092-636) or CD45 beads (Miltenyi Biotec, 130-052-301) through two consecutive LS
columns (Miltenyi Biotec, 130-042-401). Peripheral blood was collected in heparinized tubes and spun down to collect cellular components. Red blood cells were lysed (ACK lysing buffer). Remaining lymphocytes were isolated with CD11b+ magnetic beads.
Next-generation sequencing libraries and sequencing were conducted at the Center for Applied Genomics Core at the Children’s
Hospital of Philadelphia. Libraries were prepared using the 10x Genomics Chromium Single Cell 30 Reagent kit v2 per manufacturer’s
instructions. Libraries were uniquely indexed using the Chromium i7 Sample Index Kit, pooled, and sequenced on an Illumina HiSeq
sequencer in a paired-end, single indexing run. Sequencing for each library targeted 20,000 mean reads per cell. Data was processed
using the Cellranger pipeline (10x genomics, v.3.0.2) for demultiplexing and alignment of sequencing reads to the mm10 transcriptome and creation of feature-barcode matrices. Individual single cell RNaseq libraries were aggregated using the cellranger aggr
pipeline. Libraries were normalized for sequencing depth across all libraries during aggregation. Secondary analysis on the aggregated feature barcode matrices was performed using the Seurat package (v.3.0) within the R computing environment. Briefly, cells
expressing less than 200 or more than 4000 genes were excluded from further analysis. Additionally, cells expressing greater than
10% mitochondrial genes were excluded from the dataset. Batch correction was performed using a comprehensive integration algorithm (Stuart et al., 2019). Log normalization and scaling of features in the dataset was performed prior to principal component
dimensionality reduction, clustering, and visualization using UMAP. Generally, 15 PCAs were used in each analysis and resolution
was set at 0.6. Differentially expressed genes and identification of cluster or cell type specific markers were identified using a
Wilcoxon rank sum test between each defined group. P value adjustment was performed using Bonferroni correction based on total
number of genes in the aggregated dataset.
The Monocle2 package in R was used to determine pseudotime trajectories in separate cell subpopulations (Trapnell et al., 2014).
SingleR (Aran et al., 2019) in R was used to annotate cells in test dataset. Reference cells were pulled from Immgen database that is
available within the SingleR package. The program package Velocyto (La Manno et al., 2018) was used to analyze expression
dynamics in the myeloid cells of untreated tumors The program enables estimations of expression dynamics by distinguishing
unspliced and spliced mRNA reads in the cellranger single cell RNaseq output. Velocyto was run on each 10x sample using an implementation of python (v.3.6.8, cite python). Resulting loom files were aggregated using loompy. The aggregated loom file was converted to a Seurat object in R (v.3.6.2), where cell filtering, QC, and dimensional reduction were performed. The velocyto.R library was
used on the subsetted Seurat object to estimate RNA velocities of the single cells. Expression trajectories were overlaid on the Seurat
UMAP for visualization. Analysis of differential genes between clusters were performed using Ingenuity Pathway Analysis software.
Immunohistochemistry
Whole mouse brain tissues were fixed in 4% formaldehyde for 7 days and standard paraffinization was performed. Sections were cut
to 5 um thickness. Sections were rehydrated in xylene and serial ethanol concentrations. Antigen retrieval was achieved with sodium
citrate buffer (ph7 or 9) in a pressure cooker. Sections were incubated overnight at 4 C with primary antibody. Anti-mouse primary
antibodies used include the following: IbaI (Wako Chemicals, 019-19741), F4/80 (Life Technologies, MF48000), CD8 (Abcam,
ab203035), Ly6G (StemCell Technologies 60031), caspase 3 (R&D Systems, AF835), Ki67 (Abcam, ab16667), and FoxP3
(eBioscience, 14-5773). Tissues were then incubated with secondary anti-rabbit biotinylated (Vector Labs, BA-1000) or anti-rat
biotinylated secondary antibody (Vector Labs, BA-4001) for 30 minutes at room temperature. Signal was amplified with avidin/biotin
ABC complex (Vector Labs, PK-6102) and stained with DAB substrate chromogen (DAKO, 2016–10). NIS Elements BR 3.0 software
was used to capture and analyze the images. Quantification of positive CD8, F4/80, Ly6G, FoxP3, Ki67, and caspase 3 cells were
done in Imagescope. Counts are averages of 3 animals per treatment group. Two fields from each section and minimally two sections
spaced at least 100 microns apart were averaged for each animal. Tumor area for IbaI and F4/80 staining in untreated aniamls was
4345um x 3260um and for the remainder of the stains 3190um x 1974um.
RNA in situ hybridization
For Chromogenic InSitu Hybridization (CISH) staining fresh slides were sectioned, air-dried, and baked within 48hrs of staining. Staining was performed on a Bond RXm automated staining system (Leica Biosystems). For dual CISH probe staining Mm-Siglech
(Advanced Cell Diagnostics, ref#528248) and Mm-Clec12a probes (Advanced Cell Diagnostics, ref#514358-C2) were used along
with the RNAscope 2.5 LS Duplex Reagent Kit (Advanced Cell Diagnostics, 32240). Standardized protocols from Advanced Cell
Diagnostics were used without modifications. For dual CISH + IHC Mm-Siglech (same as above) or Mm-Clec12a probes (Advanced
Cell Diagnostics ref#514358) were used along with IbaI antibody (Wako 019-19741) at a 1:1K dilution with no additional retrieval
steps. For the IHC portion, a Bond Refine staining kit (Leica Biosystems, DS9800) was used with a standard protocol minus the
peroxide blocking step which was deleted. After staining slides were air-dried, coverslipped, and scanned at 40x magnification
with an Aperio CS-O slide scanner (Leica Biosystems). Two methods for quantification were performed. Cells positive for both
IbaI and Siglech or Clec12a probe staining were manually counted per field (3190um x 1974um). For quantification of dual Siglech
and Clec12a probes, we elected to use ImageJ (Trainable Weka Segmentation Plugin) to quantify pixel size and count as a surrogate
for cell count because macrophages and microglia were embedded in a field with tumor cells. The software could only discern nuclei
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of tumor cells and not the immune cells, thus precluding our ability to accurately count actual probe positive cells without IbaI staining
to identify discrete immune cells.
Flow cytometry
Whole cerebellar tissue were homogenized and myelin was removed using myelin removal beads (Miltenyi Biotec, 130-096-733).
Samples were incubated for 10 minutes with CD16/32 Fc Block (BD Biosciences, 553142) and stained on ice with primary-fluorophore conjugated antibodies for identification of cell populations by FACS. Flow cytometry was performed on an LSR II Flow
Cytometer (BD Biosciences) and analyzed using FlowJo software (Treestar). Antibodies used include the following: CD45
(BioLegend, clone 30-F11), CD11b (BioLegend, clone CBRM1/5), Ly6C (BioLegend, clone HK1.4), Ly6G (BioLegend, 1A8), CD8
(BioLegend, 53.6.7), CD3 (BioLegend, 17A2). Count beads were from ThermoFisher (C36950).
RNA isolation and qPCR analysis for gene for gene expression
CD11b+CD45hiLy6Chi and CD11b+CD45hiLy6Clo cells were sorted on FACSAria Fusion Sorter at the Children’s Hospital of
Philadelphia Flow Cytometry Core Laboratories. RNA was isolated using TrizolTM (Thermo Fisher, 15596026). Reverse transcription
was performed using High
Capacity RNA to cDNA Kit (Life Technologies). qRT-PCR was performed using ViiA7 Real-Time PCR machine. TaqMan probes
used for gene specific amplification (purchased from ThermoFisher Scientific) are listed below: Hprt (Mm03024075_m1), Clec12a
(Mm00624579_m1), Clec4a3 (Mm00462705_m1), Ccr2 (Mm04207877_m1), Fcrls (Mm00472833_m1), P2ry12 (Mm00446026_m1),
Tmem119 (Mm00525305_m1), Siglech (Mm00618627_m1).
T cell suppression assay
Mouse splenic T cells were isolated from Ptch1+/-Tp53/ mice using Pan T cell isolation Kit (Miltenyi Biotec). 4 3 104 mouse T cells
were labeled with CFSE (Life Technologies, C34554) and cultured for 3 days at 37C with 1ul of aCD3/28 bead (Thermo Fisher
Scientific, 11131D) and 15U recombinant human IL-2 (Peprotech, Inc. 200-02). CD11b+CD45hiLy6Chi, CD11b+CD45hiLy6C, and
CD11b+CD45lo cells isolated from tumors post-radiation were sorted on FACSAria Fusion Sorter. T cell proliferation was determined
by measuring CFSE signal in CD45+CD3+CD8+ cells.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses of data were carried out using the unpaired two-tailed Student’s t test for comparison between two experimental
groups. Wilcoxon signed-rank test was used in the BRETIGEA human data analysis.

e5 Cell Reports 34, 108917, March 30, 2021

Cell Reports, Volume 34

Supplemental information

Macrophages in SHH subgroup medulloblastoma
display dynamic heterogeneity
that varies with treatment modality
Mai T. Dang, Michael V. Gonzalez, Krutika S. Gaonkar, Komal S. Rathi, Patricia
Young, Sherjeel Arif, Li Zhai, Zahidul Alam, Samir Devalaraja, Tsun Ki Jerrick To, Ian
W. Folkert, Pichai Raman, Jo Lynne Rokita, Daniel Martinez, Jaclyn N. Taroni, Joshua
A. Shapiro, Casey S. Greene, Candace Savonen, Fernanda Mafra, Hakon
Hakonarson, Tom Curran, and Malay Haldar

Figure S1
a

xCell

Average immune scores normalized by rows

-......l'---'�

Group3(23)
Group4 (57)

SHH (31)
-j....i
....i
WNT(11)

0.5
0

-0.5
-1

Cibersort
Average immune scores normalized by rows

Group3(23)

1.5

Group4 (57)
SHH (31)

L_._.__.J._.L.L_.__L._____ ___.___,___,___,.,____ wNT (11)

0.5

0
-0.5
-1
-1.5

b Annotated Cd11b+ PBMC
• Beens
•
•
•
•
•
•

-10

-5

0
UMAP_1

10

'

Beens.pro
DC
Eosi n ophi l s
ILC
Macrophages
Monocytes
Neutrophils

NKcens

t

"'

�I

• Stemcells
• Tcells
• Tgd

-10

-10

e

d

,

1

0

10

C Annotated Cd11b+ cells from
2 week old mice

,.

UMAP_1

Tumor 1 (PN04)
t6

�4tt!'•···..·.,f;Jj,'
�• �4.

..
fS'
. '· "t·• ..,,) ? .,. •
, ,
•
• ·
.g�•
, -:-: ... 8' ..,
·
•

.

·-::; ....
·-.,,�...
·•.... }n:.,

111

f

Ccr2

l

Ly6c2

.
....

• Bcells
DC
• Endothelialcells
• Epi t helialcells
• Fibroblasts

• Macrophages
•
•
•
•
•

M icroglia
Monocytes
Neutrophils
Stem cells
Stromalcells

Tumor 2 (P019)
1�

Figure S1. Related to Figure 1 and 3
(a) xCell (top) and Cibersort (bottom) analysis of human patient bulk RNA-seq data
showing calculated proportions of immune cell subtypes across the different subgroups.
(b) SingleR annotation of Cd11b+ peripheral blood cells.(c) Annotation of Cd11b+ cells
from the cerebella of 2-week-old mice. (d) Unfiltered aggregate of all four samples of
myeloid cells from 2-week-old cerebella, peripheral blood, and adult tumor-bearing
cerebella. (e) UMAP of myeloid cells from each tumor displayed individually. (f) Plot of
Ccr2 and Ly6c2 showing cluster 3 has the highest expression of both, indicative of
classical monocytes.

Figure S2. Related to Figure 3 and 4
(a) Top and middle row shows violin plots ofmicroglia and monocyte-associated marker
genes (selected from publications of other tumor types). Bottom row shows that some
monocyte-associated markers are selectively higher in a few TAMoMac clusters. (b)
Heatmap of genes that are more highly expressed in microglia than monocytes.
Corresponding table show that the majority of genes are also expressed in a significant
fraction of TAMoMacs. (c) Display of RNAvelocity analysis of all TAM clusters. (d) Plots
showing expression of microglia and monocyte-specific markers by the various clusters
including CD45lo. (e) Micrograph shows RNAscope analysis with Siglech or Clec12a
probes overlaid with Ibal antibody-based immunohistochemistry. Statistical analysis:
Student's t-test. n=3 animals. Results expressed as mean± SEM. ** p-value = <0.01,
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Figure S3. Related to Figure 3
Heatmap of top 20 differentially expressed genes among monocytes and TAMoMacs (a) as
well as microglia and TAMg (b). (c) Heatmap of genes associated with specific pathways
identified by IPA analyses of TAMg clusters.
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Figure S4. Related to Figure 3 and 4
(a) Expression of anti-inflammatory and (b) inflammatory markers by monocytes, homeostatic
microglia, and TAMs. (c) Trem2 and Apoe are more highly expressed in TAMg and
TAMoMacs than in homeostatic microglia and monocytes, suggesting they are more activated.
(d) Annotation of MB TAMs in this study by using gene expression signatures from Li et. al.
confirms that cluster 0 are similar to homeostatic microglia and TAMg clusters 2 and 4 are
similar to S phase microglia. (e) Seurat analysis of a previously published murine ATRT tumor
single cell data identified Cd68+ myeloid cells (box) which were used as macrophage markers
in the original study. Further analyses of these cells (arrow) identified additional TAM clusters
(left plot) that were similar to the TAM clusters identified in this study (right plot).

Figure S5
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Figure S5. Related to Figure 5
(a) Tumors in 7-week old mice grow by approximately 20% in 5 days as measured by
MRI. After a dose of 1x 10Gy radiation, these tumors shrink by an almost similar extent
(~20%) after 5 days. n=3 animals. Results expressed as mean ± SEM. (b) Irradiated
tumors have reduced cell proliferation (Ki67+) and increased apoptosis (caspase 3+)
compared to untreated tumors. Statistical analysis: Student’s t-test. n=3 animals. Results
expressed as mean ± SEM. * p-value <0.05. Scalebar = 200um. (c) Seurat-based
clustering of myeloid cells from treated tumors (aggregated) were relabeled to match
clusters of untreated tumors. (d) Quantification of Siglech and Clec12a pixel area and
count showing an increase in Clec12a expression per field in irradiated tumors. Also see
figure 4f for description of pixel area. n=3 animals. Results expressed as mean ± SEM.
(e) Flow cytometry gating strategy for isolation of CD11b+CD45hiLy6G-Ly6chi and CD11b
+CD45hiLy6G-Ly6clo cells. (f) CD11b+CD45lo cells that contain microglia population do not
suppress CD3/CD28 stimulated splenic CD8+ cells. Statistical analysis: Student’s t-test.
n=3 samples from one mouse. These results were replicated with a second mouse. Data
expressed as mean ± SEM. * p-value < 0.05.
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Figure S6. Related to Figure 6
(a) Tumor volume at 7 weeks of age ofCcr2KO and Ccr2WT are similar. Ccr2KO responds to
radiation therapy similarly to Ccr2WT (of Fig. S5a). Results expressed as mean± SEM. n=3
animals per group. (b) Absolute count of cells by flow analysis per mm2 area of tumor shows a
trend of reduced Cd45hiLy6Chi and Cd45hiLy6Clo monocytes with increased CD45hi Ly6Ghi
neutrophils in Ccr2KO versus Ccr2WT tumors. Statistical analysis: Student's t-test. Results
expressed as mean± SEM. n=3 animals. (c) Quantification of Siglech and Clec12a pixel area
and count show less Clec12a expression per field in Ccr2KO irradiated tumors in comparison
to that of irradiated Ccr2WT (of Fig. S5c). Also see figure 4ffor description of pixel area.
Results expressed as mean± SEM. n=3 animals. (d) FoxP3+ T regulatory cells are recruited
similarly in both Ccr2WT and Ccr2KO mice. Statistical analysis: Student's t-test. Results
expressed as mean± SEM. n=3 animals. (e) UMAP of peripheral neutrophils and neutrophils
of irradiated Ccr2WT and Ccr2KO and heatmap of genes associated with IL-10 signaling
identified by IPA analysis.

